Faculty and Staff Detail
|
David L. DeRemer, Pharm.D., BCOP Clinical Assistant Professor Clinical Administrative Pharmacy |
| Contact Information | |
|---|---|
| Phone: | (706) 721-4249 |
| Email: | dderemer@mail.mcg.edu |
| Fax: | 706-721-3994 |
| Office: | HM-1214 |
| Address: |
1120 15th Street HM-1200 Augusta, GA 30912 |
| Biosketch | |||
|---|---|---|---|
| Oncology/Drug Discovery Fellowship | Univ. of Kentucky | Lexington, KY | 2004-2005 |
| Hematology/Oncology Specialty Residency | Univ. of Kentucky | Lexington, KY | 2003-2004 |
| Pharmacy Practice Residency | Univ. of Kentucky | Lexington, KY | 2002-2003 |
| Pharm.D. | Univ. of Kentucky | Lexington, KY | 2002 |
- Honors and Awards
- Board Certified Oncology Pharmacist (BCOP)
- Area of Expertise
- Bone marrow transplant
Clinical/translational research
Hematologic malignancies
Infectious disease
Supportive care
- Representative Publications
- Chapters in books:
Gerson SL, Bhalla KN, Grant S, Natarajan K, Creger, RJ, DeRemer DL,. Pharmacology and Molecular Mechanisms of Antineoplastics Agents for Hematologic Malignancies: Hoffman’s Hematology: Basic Principles and Practice 5th edition.
Journal articles:
Sisken J, DeRemer DL. Power frequency electromagnetic fields and the capacitative calcium entry system in SV40-transformed Swiss 3T3 cells. Radiation Research 2000;153:699.
Ustun C, Farrow S, DeRemer D, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplantation 2007 Jun; 39(12):807-8
Ustun C, Farrow S, El-Geneidy M, DeRemer D, Jillella A. A serious complication of allogeneic stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. Clinical Medicine:Oncology 2007: I 91-94.
Ustun C, DeRemer DL, Steele JC, et al. Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation. Int J Antimicrob Agents. 2008 Oct;32(4):365-6.
Ustun C, Kalla A, Farrow S, DeRemer DL, Jillella A. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol. 2008 Oct;83(10):825-7
DeRemer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008 Nov; 30(11):1956-75
Ustun C, DeRemer DL, Jillella AP, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. Expert Opin Investig Drugs 2009 Aug 12. [Epub ahead of print]